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ABSTRACT
Tight junction protein 1 (TJP1) has recently been proposed as a biomarker
to identify multiple myeloma (MM) patients most likely to respond to bortezomiband carfilzomib-based proteasome inhibitor regimens. Herein we report increased
expression of TJP1 during the adaptive response mediating carfilzomib resistance in
the LP-1/Cfz MM cell line. Moreover, increased TJP1 expression delineated a subset of
relapsed/refractory MM patients on bortezomib-based therapy sharing an LP-1/Cfzlike phenotype characterized by activation of interacting transcriptional effectors of
the Hippo signaling cascade (TAZ and TEAD1) and an adult tissue stem cell signature.
siRNA-mediated knockdown of TJP1 or TAZ/TEAD1 partially sensitized LP-1/Cfz
cells to carfilzomib. Connectivity Map analysis identified translation inhibitors as
candidate therapeutic agents targeting this molecular phenotype. We confirmed this
prediction by showing that homoharringtonine (omacetaxine mepesuccinate) — the
first translation inhibitor to be approved by the U.S. Food and Drug Administration —
displayed potent cytotoxic activity on LP-1/Cfz cells. Homoharringtonine treatment
reduced the levels of TAZ and TEAD1 as well as the MM-protective proteins Nrf2
and MCL1. Thus, our data suggest the importance of further studies evaluating
translation inhibitors in relapsed/refractory MM. On the other hand, use of TJP1 as
a MM biomarker for proteasome inhibitor sensitivity requires careful consideration.

INTRODUCTION

glycoprotein multidrug resistance efflux transporter,
elevated prosurvival autophagy and antioxidant defense,
altered intermediary metabolism and reprogramming of
the translation machinery as key processes mediating
acquired resistance to carfilzomib [6-9].
Recently, Orlowski and colleagues reported that
relative resistance to bortezomib and carfilzomib in some
MM cell lines was associated with decreased expression
of the tight junction protein 1 gene TJP1 (also known
as zonula occludens 1, ZO-1) and they proposed that
high TJP1 expression might be used as a biomarker of
proteasome inhibitor sensitivity in the clinic [10]. In line
with this, we observed that TJP1 transcript levels were
decreased in two of our carfilzomib-resistant MM cell

Over the past decade, the prognosis of multiple
myeloma (MM) patients has improved with the
introduction of new drugs such as the first- and secondgeneration proteasome inhibitors bortezomib and
carfilzomib [1]. Unfortunately, however, MM patients
routinely develop resistance to proteasome inhibitor-based
therapies and eventually succumb to their disease [2-5].
Toward identification of novel agents that will overcome
resistance to this class of anti-MM drugs, we have
developed isogenic models of carfilzomib resistance using
a panel of patient-derived MM cell lines [6-9]. Our studies
have revealed upregulated expression of the ABCB1/Pwww.impactjournals.com/oncoscience
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lines compared to their parental counterparts (KMS-11/
Cfz and KMS-34/Cfz versus KMS-11 and KMS-34 cells,
respectively; GEO: GSE69078). In contrast, we noted that
carfilzomib-adapted LP-1/Cfz cells — also cross-resistant
to bortezomib — expressed higher TJP1 transcript levels
than parental LP-1 cells (GEO: GSE78069) [8].
Here we confirm that TJP1 protein levels are
increased in LP-1/Cfz cells. Moreover, increased TJP1
expression delineated a subset of relapsed/refractory MM
patients on bortezomib-based therapy [11] sharing an
LP-1/Cfz-like phenotype characterized by an adult tissue
stem cell signature [12] and activation of interacting
transcriptional effectors of the Hippo signaling cascade:
TAZ (transcriptional co-activator with PDZ-binding motif
encoded by the WWTR1 gene) and TEAD1 (TEA domain
transcription factor 1) [13-16].
TAZ shares ~50% identity with YAP1 (Yes
associated protein 1), another downstream effector of the
Hippo pathway that intriguingly had previously been found
to be homozygously deleted or generally downregulated in
MM [17]. There are several structural differences between
TAZ and YAP1 that are likely related to their overlapping
yet distinct functional properties [13, 18]. Furthermore,
it is becoming increasingly appreciated that TAZ activity
is regulated by multiple inputs in addition to the Hippo
kinase cascade, including cell morphology and mechanical
cues from the extracellular microenvironment [19, 20].

siRNA-mediated knockdown of TJP1 or TAZ/
TEAD1 partially sensitized LP-1/Cfz cells to carfilzomib.
Our in vitro findings were supported by an independent
clinical data set [21] where MM patients with the LP-1/
Cfz-like molecular phenotype — i.e, high TJP1, WWTR1/
TAZ and TEAD1 expression — was associated with
inferior overall survival outcomes.
To identify novel agents that would potentially
overcome resistance to this class of anti-MM drugs, we
performed Connectivity Map (CMap) analysis [22] and
uncovered translation inhibitors whose gene expression
perturbations were significantly anticorrelated with
the expression signatures shared by LP-1/Cfz cells
and the relapsed/refractory MM cases with increased
TJP1 expression. We confirmed the CMap prediction
by showing that homoharringtonine (omacetaxine
mepesuccinate) — the first translation inhibitor to be
approved by the U.S. Food and Drug Administration —
displayed potent cytotoxic activity on LP-1/Cfz cells.
Cytotoxicity was associated with decreased TAZ and
TEAD1 protein levels as well as two proteins, Nrf2
and MCL1, previously identified by us and others as
contributing to MM drug resistance [8, 9, 23-25].

RESULTS AND DISCUSSION
TJP1 is associated with drug resistance in LP-1/
Cfz and RPMI-8226/Dox40 MM cells
In prior work, we found that the transcription factor
NF-E2 p45-related factor 2 (Nrf2; gene symbol NFE2L2)
contributes to the carfilzomib-resistant phenotype in LP-1/
Cfz cells characterized by an epithelial-to-mesenchymal
transition (EMT)-like expression signature [8]. EMT
is a developmental program that is often activated
during tumor metastasis resulting in the gain of stem
cell properties by the malignant cells [26]. During
developmental EMT, epithelial intercellular junctions
are disrupted and TJP1 is coordinately downregulated
with CDH1 (E-cadherin) [27]. Cell surface expression of
E-cadherin was decreased on LP-1/Cfz cells compared
to parental LP-1 cells [8], but TJP1 protein levels were
predicted to be ~2-fold increased (Table S1: Expression
changes, TJP1 202011_at probe set). Of potential
relevance in this regard, upregulation of TJP1 has been
associated with invasion and metastasis in certain tumor
systems [28-30].
Western blot analysis showed significantly higher
TJP1 levels in LP-1/Cfz compared to parental LP-1 cells
(Figure 1). For comparison, we also examined TJP1
levels in RPMI-8226 MM cells analyzed by Orlowski and
colleagues [10] together with three drug-resistant RPMI8226 derivatives: RPMI-8226/Dox40 cells, selected for
resistance to doxorubicin [31]; RPMI-8226/LR5 cells,

Figure 1: TJP1 protein levels are increased in
carfilzomib-resistant LP-1/Cfz cells. Western blot analysis

showing significantly higher TJP1 levels in LP-1/Cfz compared
to parental LP-1 cells. Note that TJP1 levels are also increased in
doxorubicin-resistant RPMI-8226/Dox40 compared to parental
RPMI-8226 cells.
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Increased TJP1 expression during disease
progression identifies a subset of relapsed/
refractory MM patients on bortezomib-based
therapy exhibiting an LP-1/Cfz-like phenotype

selected for resistance to melphalan [32]; and RPMI-8226/
MR20 cells, selected for resistance to mitoxantrone [33].
TJP1 levels were increased in RPMI-8226/Dox40 cells;
however, no significant changes were observed in the
other derivatives (Figure 1). This was noteworthy because
we and others have shown that RPMI-8226/Dox40 cells
are cross-resistant to both carfilzomib and bortezomib
due in part to upregulation of ABCB1/P-glycoprotein [6,
34]. These results indicated that overexpression of TJP1
in MM cells is not universally associated with increased
sensitivity to proteasome inhibitors. Consequently,
we were interested in determining whether there were
instances where MM patients who developed resistance
to proteasome inhibitor-based therapies also exhibited
increased TJP1 expression and whether they might share
similar properties with LP-1/Cfz or RPMI-8226/Dox40
cells.

We first examined TJP1 levels in the GEO:
GSE31161 data set that contains expression profiling
data at diagnosis and relapse for MM patients treated
with the University of Arkansas for Medical Sciences
(UAMS) Total Therapy (TT3) protocol which incorporates
bortezomib up-front into the Total Therapy 2 (TT2)
tandem transplant regimen [11]. Out of 30 evaluable
patients, 13 (43.3%) had significantly higher TJP1
expression at relapse (TJP1-up patients: ~6.5-fold up;
log2FC for the TJP1 202011_at probe set, 2.70; P = 7.63
× 10-4) and 17 (56.7%) had significantly lower TJP1
expression at relapse (TJP1-down patients: ~3.7-fold

Figure 2: Increased expression of TJP1 is associated with upregulation of TAZ-TEAD activity and adult stem cell genes
in LP-1/Cfz cells and TT3 protocol patients with relapsed/refractory disease (GEO: GSE31161). A. GSEA enrichment

plots of the Cordenonsi YAP Conserved Signature for triplicate samples of LP-1/Cfz versus parental LP-1 cells (top), for TT3 patients with
increased TJP1 levels at relapse (middle), and for TT3 patients with decreased TJP1 levels at relapse (bottom). B. GSEA enrichment plots
of the Wong Adult Tissue Stem Module for triplicate samples of LP-1/Cfz versus parental LP-1 cells (top), for TT3 patients with increased
TJP1 levels at relapse (middle), and for TT3 patients with decreased TJP1 levels at relapse (bottom). NES, normalized enrichment score.
www.impactjournals.com/oncoscience
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down; log2FC for the TJP1 202011_at probe set, -1.88;
P = 3.98 × 10-3) (Table S1: Expression changes). Neither
group had increased ABCB1 expression at relapse (Table
S1: Expression changes, ABCB1 209993_at probe set).
Next we applied Gene Set Enrichment Analysis
(GSEA) to compare the two TT3 patient subsets with
LP-1/Cfz cells [35]. Similar to LP-1/Cfz cells, significant
enrichment of an EMT-like signature (Hallmark Epithelial
Mesenchymal Transition) was observed for TJP1-up
patients (normalized enrichment score [NES] = 1.78, P
< 0.001) (Table S1: Hallmark collection). Also, as with

LP-1/Cfz cells, significant enrichment of an Nrf2 target
gene set (NFE2L2.V2) was found for TJP1-up patients
(NES = 1.43, P < 0.001) (Table S1: C6 Oncogenic
signatures). Interestingly, LP-1/Cfz cells and both TT3
patient subsets showed enrichment of the Cordenonsi YAP
Conserved Signature associated with cancer stem cellrelated properties (Figure 2A; Table S1: C6 Oncogenic
signatures). Notably, among the 3,400 gene sets in the
C2.CGP Chemical and genetic perturbations collection,
the Wong Adult Tissue Stem Module, containing genes
coordinately upregulated in a compendium of adult tissue

Figure 3: TAZ-TEAD1 activation in LP-1/Cfz cells confers resistance to carfilzomib. A. TAZ levels are increased in LP-1/
Cfz (Cfz) versus parental LP-1 cells (1.6 ± 0.3-fold, n = 10, P < 0.01). Cells were pretreated with MG-132 (15 μM) for 18 hours to prevent
proteasomal degradation. B. TEAD1 levels are increased in LP-1/Cfz (Cfz) versus parental LP-1 cells (2.2 ± 0.3-fold, n = 10, P < 0.01).
Cells were pretreated with MG-132 (15 μM) for 18 hours to prevent proteasomal degradation. C. siRNA-mediated knockdown of TAZ
slightly sensitized LP-1/Cfz cells to carfilzomib. Consistent with low YAP1 levels in LP-1/Cfz cells, siRNA-mediated knockdown of YAP1
in concert with TAZ did not meaningfully enhance sensitization of the cells to the drug. LP-1/Cfz cells were significantly sensitized to
carfilzomib by combined siRNA-mediated knockdown of TAZ and TEAD1. No effects were observed on parental LP-1 cells under any of
the conditions. Cells were treated with carfilzomib (12.5 nM) for 48 hours after transient transfection and cell viability was determined by
alamarBlue assay. *, P = 0.04 vs negative siRNA control (siNeg, n = 3). D, E. siRNA-mediated knockdown of TAZ and TEAD1 in LP-1/
Cfz cells was accompanied by decreased TAZ (40 ± 15% decrease) (D) and TEAD1 (57 ± 6% decrease) (E) levels.
www.impactjournals.com/oncoscience
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Increased TJP1 expression separates out MM
patients with poor prognosis into a higher-risk
LP-1/Cfz-like subset

stem cells [12], was enriched in both LP-1/Cfz cells and
TJP1-up patients (Figure 2B). Conversely, TJP1-down
patients had negative enrichment of this gene set (Figure
2B) and instead had enrichment of an embryonic stem celllike signature (Wong Embryonic Stem Cell Core; NES =
3.42; P < 0.001) [12]. Collectively, the results indicated
that the 30 MM cases that progressed on bortezomib-based
TT3 therapy had acquired transcriptional programs shared
with stem cells. Increased TJP1 expression delineated
a TT3 subset most closely resembling LP-1/Cfz cells:
i.e., exhibiting EMT-like features, Nrf2 activation and
enrichment of an adult tissue stem cell signature.

Acquisition of EMT-like features was previously
shown to promote the extramedullary dissemination
of MM cells [39]. Gene profiling of extramedullary
MM has revealed differential expression of adhesion
molecules and factors that stimulate angiogenesis [40].
In this regard, significant enrichment of an angiogenesis
signature (Hallmark Angiogenesis) was observed for
both LP-1/Cfz cells and for TJP1-up patients (NES =
1.68, P < 0.001 and NES = 1.92, P < 0.001, respectively)
(Table S1: Hallmark collection). Moreover, we noted that
WWTR1/TAZ was included among the 156 upregulated
genes in extramedullary MM [40]. A separate gene
expression profiling study conducted by the UAMS group
showed that extramedullary MM was more prevalent
in patients with high-risk disease that includes those in
the proliferation-related “PR” subgroup [41]. The PR
subgroup was previously defined in an independent
cohort of newly diagnosed patients treated on UAMS
TT2 and TT3 protocols (GEO: GSE2658) [21]. We used
the PROGgeneV2 prognostic biomarker identification
tool to investigate the impact of TJP1 expression on the
overall survival outcomes of MM patients in the GEO:
GSE2658 data set [42]. Using median gene expression
values as bifurcation points, Cox proportional hazards
regression analysis showed that MM patients in the PR
subgroup with the Cordenonsi YAP Conserved Signature
(57 genes) had significantly inferior overall survival,
with worse prognosis when high level TJP1 coexpression
was also considered (Figure 4A). High expression of
the top 50 genes in the leading edge subset of the LP-1/
Cfz Wong Adult Tissue Stem Module (721 genes total)
was also associated with adverse outcomes. Within these
parameters, TJP1 expression levels did not provide any
additional prognostic information (Figure 4B).
Only 2 out of the top 50 genes in the leading edge
subset of the LP-1/Cfz Wong Adult Tissue Stem Module
are shared with the Cordenonsi YAP Conserved Signature:
ITGB5 and CRIM1, which were also among the 156
upregulated genes in extramedullary MM [40]. ITGB5,
encoding β5-integrin, was previously demonstrated to
play a critical role in EMT associated with the tumorigenic
potential of breast cancer cells [43]. CRIM1 encodes
cysteine rich transmembrane bone morphogenetic protein
regulator 1, which has been shown to regulate integrin
signaling and angiogenesis during development [44, 45].
Increased expression of both genes has been associated
with the acquisition of chemoresistance [46, 47]. Notably,
ITGB5 and CRIM1 are coexpressed with WWTR1/TAZ (top
20 gene neighbors) across 947 cell lines in the Cancer Cell
Line Encyclopedia (CCLE; Figure S1) [48]. Furthermore,

Elevated TAZ and TEAD1 protein levels provide
an explanation for the Cordenonsi YAP Conserved
Signature in LP-1/Cfz cells
The Cordenonsi YAP Conserved Signature,
representing a list of evolutionary conserved target
genes of the YAP1 transcriptional effector of the Hippo
signaling pathway, was the top-ranked gene set for LP-1/
Cfz cells (Table S1: C6 Oncogenic signatures). We had
not focused on it earlier because, as previously reported
for most MM and other hematopoietic cancer cells [17],
YAP1 mRNA levels were low in LP-1 cells and were not
increased in LP-1/Cfz cells (~1.2-fold down; log2FC for
the YAP1 213342_at probe set, -0.24; P = 0.14) (Table
S1: Expression changes). Upon further investigation, we
learned that the Cordenonsi YAP Conserved Signature
was enriched in breast cancer cells undergoing EMT that
resulted in the activation of TAZ, a paralog of YAP1,
which conferred stem cell-like properties on the tumor
cells [36]. Slightly increased expression of the TAZencoding gene WWTR1 was observed in LP-1/Cfz cells
(~1.3-fold up; log2FC for the WWTR1 202133_at probe
set, 0.41; P = 0.05) (Table S1: Expression changes). In
addition, TEAD1, a key DNA-binding transcription factor
partner of TAZ [14, 15], was highly expressed in both
LP-1 and LP-1/Cfz cells (TEAD1 224955_at probe set;
GEO: GSE78069). As anticipated [17], YAP1 protein
levels were low in LP-1 cells (below detection by western
blotting). Although WWTR1/TAZ mRNA levels were
comparable to YAP1 mRNA levels (GEO: GSE78069),
TAZ protein could be detected in LP-1 cells and elevated
levels were observed in LP-1/Cfz cells (Figure 3A).
Strikingly, TEAD1 protein levels were also markedly
increased in LP-1/Cfz cells (Figure 3B). These findings
were reminiscent of the translational upregulation we
previously documented for Nrf2 in LP-1/Cfz cells [8, 9].
Importantly, combined knockdown of TAZ and TEAD1
with previously validated siRNAs [37, 38] partially
sensitized LP-1/Cfz cells to carfilzomib (P = 0.04; Figure
3C-E).

www.impactjournals.com/oncoscience
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Figure 4: Prognostic value of TJP1 expression in MM patient survival outcomes. KaplanMeier survival plots of 47 MM
patients in the high-risk PR subgroup (GEO: GSE2658) created using PROGgeneV2: A. Cordenonsi YAP Conserved Signature minus (left)
and plus (right) TJP1 coexpression. B. Leading edge subset (top 50 genes) of the LP-1/Cfz Wong Adult Tissue Stem Module minus (left)
and plus (right) TJP1 coexpression. C. WWTR1/TAZ expression (left) plus coexpression of TEAD1, ITGB5, CRIM1 and TJP1 (right).
Median gene expression values were used as bifurcation points.
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TJP1 is among the top 20 gene neighbors of both TEAD1
and ITGB5 in the CCLE (Figure S1). Kaplan-Meier plots
indicated significant segregation in survival outcomes for
patients in the PR subgroup with high versus low WWTR1/
TAZ expression (hazard ratio, HR = 2.7; 95% confidence
interval/CI, 1.34-5.44; P = 0.006). Increasing risk of
mortality was observed when high level coexpression of
TEAD1, ITGB5 and CRIM1 (HR = 3.98; 95% CI, 1.639.68; P = 0.002) and TEAD1, ITGB5, CRIM1 plus TJP1
were also taken into consideration (HR = 7.37; 95% CI,
1.96-27.67; P = 0.003) (Figure 4C). It should be mentioned
that high level expression of TEAD1 had previously been
associated with high-risk disease and the PR subgroup
in MM [49]. However, the biological relevance of this
observation has not been heretofore appreciated.

Tissue Stem Module and the GO Anchoring Junction
gene sets were all significantly enriched (Figure 6B).
Significant enrichment of the Cordenonsi YAP Conserved
Signature was previously observed after development of
chemoresistance in melanoma cells [50]. In that study, in
which TJP1 was one out of 426 significantly upregulated
genes common to two cell lines selected for resistance to
the BRAF inhibitor PLX4032 (vemurafenib) (see Table
EV1 of ref. [50]), increased YAP/TAZ transcriptional
activity was accompanied by enhanced YAP/TAZ nuclear
localization.
In line with this, TAZ predominantly localized to
the nucleus in a characteristic punctate staining pattern
[13] as well as to the perinuclear region of LP-1/Cfz
cells (Figure 7A, top panels). Lower levels of TAZ were
present in parental LP-1 cells with a greater distribution
in the perinuclear region (Figure 7A, bottom panels). By
comparison, TJP1 was present in the cytoplasm, plasma
membrane and nucleus of LP-1/Cfz cells (Figure 7A, top
panels) whereas it was primarily detected in the cytoplasm
of parental LP-1 cells (Figure 7A, bottom panels). Some
colocalization of TJP1 with TAZ was observed in LP-1/
Cfz cells but not within the punctate nuclear structures.
These results indicated that, while TJP1 is able to bind to
TAZ in vitro [51], functional complexes between TJP1 and
TAZ are not responsible for TAZ nuclear retention [52,
53].
To directly test whether TJP1 contributes to
carfilzomib resistance, we transfected LP-1/Cfz cells
with two previously validated TJP1 siRNAs [54, 55].
We confirmed that both siRNAs resulted in a significant
decrease in TJP1 protein levels (64 ± 4% decrease; n =
3) (Figure 7B). As illustrated in Figure 7C, knockdown
of TJP1 with both siRNAs modestly, but significantly,
sensitized LP-1/Cfz cells to carfilzomib (P = 0.03).

Increased TJP1 expression contributes to LP-1/
Cfz-like high-risk MM phenotype and carfilzomib
resistance
Although TJP1 was not identified as a YAP/TAZ
target gene in the Cordenonsi YAP Conserved Signature,
it was a member of the top two overlapping gene sets in
the MSigDB C5.CC Gene Ontology Cellular Component
collection (580 total gene sets): GO Cell Junction (13 out
of 57 genes; P = 1.26 × 10-9) and GO Anchoring Junction
(9 out of 57 genes; P = 9.30 × 10-9) (Figure 5A). Both
gene sets were selectively enriched in LP-1/Cfz cells and
TJP1-up patients (Figure 5B; Table S1: C5 GO gene sets).
Conversely, TJP1-down patients had negative enrichment
of these gene sets (Figure 5B; and data not shown).
Moreover, ITGB5 was included with TJP1 in the LP-1/
Cfz leading edge subset of the GO Anchoring Junction
gene set (Figure 5C). Indeed, enrichment of canonical
pathways and GO-term gene sets involving cell contacts
— previously noted to be overrepresented within the
TAZ interactome data set [18] — was observed for LP-1/
Cfz cells and TJP1-up patients (Figure 5A,D; Table S1:
C2.CP Canonical pathways, C5 GO gene sets), suggesting
biological relevance of TJP1 upregulation [19, 20].
To further explore the potential functional
significance of increased TJP1 expression with respect to
the LP-1/Cfz-like high-risk MM phenotype, we stratified
the 30 TT3 relapsed samples in the GEO: GSE31161 data
set on the basis of TJP1 expression (TJP1 202011_at
probe set). While the samples did not perfectly segregate
into two separate groups, those with the highest TJP1
mRNA levels belonged to the TJP1-up subset (increased
TJP1 expression at relapse) and those with the lowest
TJP1 mRNA levels belonged to the TJP1-down subset
(decreased TJP1 expression at relapse) (Figure 6A).
When we performed GSEA to identify gene sets that
positively correlated with TJP1 expression, we found that
the Cordenonsi YAP Conserved Signature, the Wong Adult

www.impactjournals.com/oncoscience

Translation inhibitors as potential treatment for
relapsed/refractory MM
Consistent with the post-transcriptional increase
in TEAD1 (and, to some degree, TAZ) levels and the
translational adaptations that resulted in increased Nrf2
protein levels in LP-1/Cfz cells [8, 9], pathways related to
translational control of gene expression were among the
overrepresented processes shared with TJP1-up patients
(Figures 5D, 6B; Table S1: C2.CP Canonical pathways,
C5 GO gene sets). In a complementary approach, when we
queried the Connectivity Map database (CMap Build 02),
a reference collection of 6,100 gene expression signatures
from four human cell lines treated with 1,309 small
molecule perturbagens [22], we identified gene expression
perturbations by cycloheximide and emetine as the only
ones that were significantly negatively correlated with the
expression signatures linked to both carfilzomib resistance
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Figure 5: Gene Ontology terms and canonical pathways involving cell contacts are enriched in LP-1/Cfz cells and TT3
protocol patients (GEO: GSE31161) with increased TJP1 levels at relapse. A. Bar graphs showing the top 10 gene sets out of

580 total gene sets in the MSigDB C5.CC Gene Ontology Cellular Component collection that overlap with the Cordenonsi YAP Conserved
Signature. P values were calculated using the hypergeometric distribution. See also Table S1: GO gene sets. B. GSEA enrichment plots of
the GO Anchoring Junction gene set for triplicate samples of LP-1/Cfz versus parental LP-1 cells (top), for TT3 patients with increased
TJP1 levels at relapse (middle), and for TT3 patients with decreased TJP1 levels at relapse (bottom). NES, normalized enrichment score. C.
Heat map of the leading edge subset of genes in the GO Anchoring Junction gene set upregulated in LP-1/Cfz (Cfz) versus parental LP-1
cells (triplicate samples). Probe sets for TJP1, ITGB5 and RND3 are highlighted. See text for details. D. Bar graphs showing the top 10
gene sets out of 1329 total gene sets in the MSigDB C2.CP Canonical pathways collection that overlap with the GO Anchoring Junction
gene set. Note that 5 out of the 10 gene sets involve translational control mechanisms. P values were calculated using the hypergeometric
distribution. See also Table S1: C2.CP Canonical pathways.
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in LP-1/Cfz cells and the TJP1-up MM cases (P ≤ 0.05)
(Table S1: CMap Build 02). These results suggested that
translation inhibitors may modulate chemosensitivity
of MM cells with these shared features by reversing the
expression of the signature genes responsible [56, 57].
We tested emetine and found that it displayed singleagent activity against LP-1/Cfz cells (Figure 8A, top).
This result prompted us to examine the effect of the
FDA-approved translation inhibitor homoharringtonine
(omacetaxine mepesuccinate) [58], which had previously
been demonstrated to induce apoptosis but had not been

reported to overcome drug resistance in MM cells [59].
Treatment with homoharringtonine displayed potent
cytotoxicity against LP-1/Cfz cells over a concentration
range that was 10-fold lower than that of emetine (Figure
8A, bottom). During revision of this manuscript, a
new version of the CMap database was released that
is accessible via CLUE (CMap and LINCS Unified
Environment: [clue.io]). The Touchstone dataset of
CLUE contains ~50,000 gene expression signatures from
nine human cell lines treated with 2,911 FDA-approved
and clinical trial drugs. It was especially noteworthy

Figure 6: Enriched MSigDB gene sets in MM patients enrolled on the TT3 protocol with high TJP1 levels at relapse.

A. Heat map of TJP1 neighbors for 30 TT3 relapsed samples in the GEO: GSE31161 data set stratified on the basis of TJP1 202011_at
probe set levels. Asterisks indicate TJP1-up patients (see Table S1: GSE31161, TT3 samples). B. Enrichment plots of selected gene sets
containing genes whose expression is highly correlated with TJP1 expression. NES, normalized enrichment score.
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Figure 7: Subcellular localization and knockdown of TJP1 in LP-1/Cfz cells. A. LP-1/Cfz and parental LP-1 cells were
cultured on poly-L-lysine-coated microscope slides. Cells were fixed and labeled with anti-TJP1 (Alexa Fluor 488, green) or anti-TAZ
(Alexa Fluor 568, red) antibodies. Cell nuclei were stained with TOTO-3 (blue). B. siRNA-mediated knockdown of TJP1 mRNA was
accompanied by decreased TJP1 levels (64 ± 4% decrease; n = 3). C. Knockdown of TJP1 mRNA using two specific siRNAs (siTJP1 #1,
siTJP1 #2) sensitizes LP- 1/Cfz cells to carfilzomib. Cells were cultured on fibronectin-coated plates and treated with carfilzomib (6 nM)
for 48 hours after transient transfection; cell viability was determined by alamarBlue assay. *, P = 0.03 vs negative siRNA control (siNeg,
n = 3).
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Concluding remarks

therefore that expression signatures generated by
homoharringtonine as well as emetine and cycloheximide
— in fact, translation inhibitors in general — were among
those displaying the most significant negative correlations
with the LP-1/Cfz and TJP1-up MM signatures (Table S1:
CMap CLUE).
Translation inhibitors induce cell death by reducing
the levels of short-lived prosurvival proteins like the
BCL2 family member MCL1 [59]. TAZ is an unstable
protein with a half-life of ~2 hours in other cell types
[60]. Treatment of LP-1/Cfz cells with emetine or
homoharringtonine led to reduced amounts of TAZ; the
levels of TEAD1, which has a half-life of ~16 hours in
fibroblasts [61], were also reduced under the 18-hour
treatment conditions employed (Figure 8B). Nrf2 is also a
short-lived protein [62], and Nrf2 levels were significantly
reduced by both translation inhibitors (Figure 8C).
Moreover, recent studies have provided additional support
for an important role of MCL1 in MM cell survival [24,
25] (ClinicalTrials.gov: NCT02675452, NCT02992483).
Both emetine and homoharringtonine significantly reduced
MCL1 levels (Figure 8C).

A recent report by Orlowski and colleagues
suggested the use of TJP1 as a biomarker to identify
MM patients most likely to benefit from proteasome
inhibitors [10]. The investigators proposed that high TJP1
levels resulted in decreased proteasome activity due to
suppression of expression of the PSMB8 gene encoding
the immunoproteasome β5i/LMP7 (chymotrypsin-like)
subunit targeted by carfilzomib and bortezomib as well
as the PSMB9 gene encoding the β1i/LMP2 (caspaselike) subunit that is also targeted by bortezomib [10]. This
model does not hold for LP-1/Cfz cells nor for the subset
of MM patients on bortezomib-based therapy analyzed
here. In the case of LP-1/Cfz cells, PSMB8 and PSMB9
were downregulated concomitant with increased TJP1
expression (~1.5-fold; P = 2.71 × 10-5 and 1.58 × 10-5,
respectively) but this was associated with acquisition of
carfilzomib resistance, whereas there were no significant
differences in PSMB8 or PSMB9 expression levels during
disease progression in the TJP1-up patients (Table S1:
PSMB8 209040_s_at and PSMB9 204279_at probe sets).

Figure 8: Cytotoxic activity of translation inhibitors against LP-1/Cfz cells. A. Cells were treated with the indicated
concentrations of emetine (top) or homoharringtonine (bottom) for 48 hours and cell viability was determined by alamarBlue assay. B.
Treatment with emetine (0.3 µM) or homoharringtonine (30 nM) for 18 hours decreases TAZ (top) and TEAD1 (bottom) levels in LP-1/
Cfz cells. C. Treatment with emetine (0.3 µM) or homoharringtonine (30 nM) for 18 hours decreases Nrf2 (top) and MCL1 (bottom) levels
in LP-1/Cfz cells.
www.impactjournals.com/oncoscience
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The molecular association between increased TJP1
expression and TAZ/TEAD activation and exactly how
this contributes to proteasome inhibitor resistance and
the LP-1/Cfz-like high-risk MM phenotype remain to be
clarified. A number of tight junction-associated signaling
pathways have been described [63]. One possibility is that
upregulated TJP1 expression activates TAZ similar to
that previously reported for the PDZ domain-containing
tight junction protein PARD3 which involves protein
phosphatase 1 [64]. Another candidate effector for future
study is Rnd3/RhoE, a multifunctional Rho family
GTPase that acts both as a regulator of the cytoskeleton
and translation initiation [65, 66]. Rnd3 participates in
focal adhesion and tight junction formation together with
TJP1 (Figure 5C) [67] as well as in tumor cell migration
[68, 69]. We previously identified RND3 as a novel Nrf2upregulated target in LP-1/Cfz cells associated with
the translational reprogramming leading to carfilzomib
resistance [8, 9].
In any event, our data indicate the importance of
additional patient stratification when considering use of
TJP1 as a biomarker of proteasome inhibitor sensitivity
in MM. On the other hand, our findings with translation
inhibitors in LP-1/Cfz cells support further preclinical
testing and potential clinical evaluation of these agents in
relapsed/refractory MM.

819); and anti-α-tubulin mouse mAb (DM1A) (EMD
Millipore Corporation, Cat. No. CP06). Carfilzomib
(Cat. No. A-1098) was obtained from Active Biochem;
emetine (Cat. No. 32-469-3250MG) was purchased from
Fisher Scientific; and homoharringtonine (omacetaxine
mepesuccinate) (Cat. No. SML1091) was from SigmaAldrich.

Confocal microscopy
Immunofluorescence confocal microscopy was
performed essentially as described previously [7, 8].
In brief, cells were plated onto poly-L-lysine-coated
microscope slides (Thermo Fisher Scientific, Cat. No. 50279-88) in 10 cm cell culture dishes (5 x 105 cells in 1 ml
of medium per slide) [70]. After 3 hours, 10 ml of medium
was added and the cells were cultured overnight. Attached
cells were fixed in 3.7% formaldehyde for 5 minutes at
room temperature and permeabilized with 0.5% Triton
X-100 in phosphate-buffered saline (PBS) for 15 minutes
at room temperature. Following permeabilization, the
cells were rinsed with PBS and blocked in PBS containing
10% goat serum and 0.01% Triton X-100 for 40 minutes
at room temperature. The cells were then incubated with
anti-TJP1 and anti-TAZ antibodies diluted 1:500 in PBS
containing 1% goat serum and 0.01% Triton X-100 for
1 hour at room temperature. The cells were rinsed three
times with PBS and then incubated with Alexa Fluor
488-conjugated goat anti-mouse (Thermo Fisher Scientific,
Cat. No. A-11001) and Alexa Fluor 568-conjugated goat
anti-rabbit (Thermo Fisher Scientific, Cat. No. A-11036)
secondary antibodies diluted 1:500 in PBS containing 1
μM TOTO-3 (Thermo Fisher Scientific, Cat. No. T3604),
1% goat serum and 0.01% Triton X-100 for 1 hour at room
temperature. The cells were rinsed with PBS and mounted
with Fluoromount G (Electron Microscopy Sciences).
Imaging analysis was performed on an LSM 710 laser
scanning confocal microscope equipped with Zen software
(Carl Zeiss Microscopy).

MATERIALS AND METHODS
Cell culture
Carfilzomib-resistant LP-1/Cfz cells have been
described previously [8]. RPMI-8226 cells were obtained
from the American Type Culture Collection (Manassas,
VA). Doxorubicin-resistant RPMI-8226/Dox40 cells
[31], melphalan-resistant RPMI-8226/LR5 cells [32] and
mitoxantrone-resistant RPMI-8226/MR20 cells [33] were
kindly provided by Dr. William Dalton (Moffitt Cancer
Center, Tampa, FL). Cells were cultured in RPMI 1640
with GlutaMAX (Thermo Fisher Scientific) supplemented
with 10% fetal bovine serum (Cambrex BioScience), 100
U/ml penicillin and 100 μg/ml streptomycin. Cultures
were maintained at 37°C in a humidified atmosphere
containing 5% CO2.

siRNA transfections
RNA interference was performed as described
previously [8] using validated Silencer® Select siRNAs
for WWTR1/TAZ (s24789) [37], TEAD1 (s13961) [38],
YAP1 (s20366) [38], TJP1 (s14155, s14156) [54, 55] or
a negative control siRNA (Cat. No. 4390843) (Thermo
Fisher Scientific). Briefly, 2 x 106 cells per ml were seeded
into 24 well plates in 100 μl aliquots. Each well received
a mixture of siRNAs (750 ng) and HiPerFect reagent (6
μl) in 100 μl serum-free culture medium preincubated for
15 minutes. After 5 hours, the cells were diluted to 6 x
105 per ml in complete medium. Cells (3 x 105 per ml)
were seeded into 96 well plates and treated with a range
of carfilzomib concentrations.

Antibodies and reagents
The following antibodies were used: anti-ZO-1/
TJP1 (ZO1-1A12) (Fisher Scientific, Cat. No. 339100); anti-TAZ (V386) (Cell Signaling Technology,
Cat. No. 4883); anti-TEF-1(TEAD1) (Clone 31/TEF-1)
(BD Biosciences, Cat. No. 610922); anti-Nrf2 (H-300)
(Santa Cruz Biotechnology, Cat. No. sc-13032); antiMCL1 (S-19) (Santa Cruz Biotechnology, Cat. No: scwww.impactjournals.com/oncoscience
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Cytotoxicity assay

mechanisms. Oncotarget. 2013; 4: 2186-2207.
5.

Abraham J, Salama NN, Azab AK. The role of
P-glycoprotein in drug resistance in multiple myeloma.
Leuk. Lymphoma. 2015; 56: 26-33.

6.

Hawley TS, Riz I, Yang W, Wakabayashi Y, DePalma L,
Chang YT, Peng W, Zhu J, Hawley RG. Identification of
an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant
myeloma subpopulation by the pluripotent stem cell
fluorescent dye CDy1. Am. J. Hematol. 2013; 88: 265-272.

Gene expression analysis

7.

Gene expression profiling data for LP-1/Cfz and
parental LP-1 MM cells is available at GEO: GSE78069.
Datasets for MM patients are available at GEO: GSE2658
and GEO: GSE31161.

Riz I, Hawley TS, Hawley RG. KLF4-SQSTM1/p62associated prosurvival autophagy contributes to carfilzomib
resistance in multiple myeloma models. Oncotarget. 2015;
6: 14814-14831.

8.

Riz I, Hawley TS, Marsal JW, Hawley RG. Noncanonical
SQSTM1/p62-Nrf2 pathway activation mediates
proteasome inhibitor resistance in multiple myeloma cells
via redox, metabolic and translational reprogramming.
Oncotarget. 2016; 7: 66360-66385.

9.

Hawley RG, Riz I. Nrf2: not “lost in translation”. Aging
(Albany NY). 2016; 8: 3153-3154.

Cells were treated with carfilzomib and agents at the
indicated concentrations and cell growth was measured
using the alamarBlue cell viability and proliferation
reagent (Thermo Fisher Scientific) as described previously
[6-8], except that assays were performed on fibronectincoated plates (Fisher Scientific, Cat. No. 08-774-60) [71].

Gene set enrichment analysis (GSEA)
GSEA [26] was performed using the MSigDB v5.2
collections. Statistical significance of the enrichment score
was assessed by 1,000 gene set permutations.

10. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G,
Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie
B, Usmani SZ, Zhang Q, Crowley J, et al. Tight junction
protein 1 modulates proteasome capacity and proteasome
inhibitor sensitivity in multiple myeloma via EGFR/JAK1/
STAT3 signaling. Cancer Cell. 2016; 29: 639-652.

ACKNOWLEDGEMENTS
We thank Leif Bergsagel for originally providing
the LP-1 MM cell line and we are grateful to William
Dalton for providing the RPMI-8226/Dox40, RPMI-8226/
LR5 and RPMI-8226/MR20 MM cell lines. This work was
supported by a Grant from the Katzen Cancer Research
Center at the GW Cancer Center and by a generous
philanthropic gift from Marc Cohen.

11. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot
G, van Rhee F, Crowley J, Shaughnessy JD,Jr, Barlogie B.
Sustained complete remissions in multiple myeloma linked
to bortezomib in total therapy 3: comparison with total
therapy 2. Br. J. Haematol. 2008; 140: 625-634.
12. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang
HY. Module map of stem cell genes guides creation of
epithelial cancer stem cells. Cell Stem Cell. 2008; 2: 333344.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

13. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA,
Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley
LC, Yaffe MB. TAZ: a novel transcriptional co-activator
regulated by interactions with 14-3-3 and PDZ domain
proteins. EMBO J. 2000; 19: 6778-6791.

REFERENCES
1.

Anderson KC. Progress and paradigms in multiple
myeloma. Clin. Cancer Res. 2016; 22: 5419-5427.

2.

Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson
PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau
P, LeLeu X, Hulin C, Klein SK, et al. Risk of progression
and survival in multiple myeloma relapsing after therapy
with IMiDs and bortezomib: a multicenter international
myeloma working group study. Leukemia. 2012; 26: 149157.

3.

4.

14. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong
W. TEADs mediate nuclear retention of TAZ to promote
oncogenic transformation. J. Biol. Chem. 2009; 284: 1434714358.
15. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y,
Lei QY, Guan KL. TEAD transcription factors mediate the
function of TAZ in cell growth and epithelial-mesenchymal
transition. J. Biol. Chem. 2009; 284: 13355-13362.

Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial
S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan
A, Buadi F, Reu FJ, et al. A phase 2 study of single-agent
carfilzomib (PX-171-003-A1) in patients with relapsed and
refractory multiple myeloma. Blood. 2012; 120: 2817-2825.

16. Kim MH, Kim J. Role of YAP/TAZ transcriptional
regulators in resistance to anti-cancer therapies. Cell Mol.
Life Sci. 2017; 74: 1457-1474.
17. Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L,
ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni
M, Marcatti M, Richardson PG, et al. Rescue of Hippo

Abdi J, Chen G, Chang H. Drug resistance in multiple
myeloma: latest findings and new concepts on molecular

www.impactjournals.com/oncoscience

13

Oncoscience

coactivator YAP1 triggers DNA damage-induced apoptosis
in hematological cancers. Nat. Med. 2014; 20: 599-606.

protein-1 in human melanoma associates with N-cadherin
and contributes to invasion and adhesion. Am. J. Pathol.
2005; 166: 1541-1554.

18. Kohli P, Bartram MP, Habbig S, Pahmeyer C, Lamkemeyer
T, Benzing T, Schermer B, Rinschen MM. Labelfree quantitative proteomic analysis of the YAP/TAZ
interactome. Am. J. Physiol. Cell. Physiol. 2014; 306:
C805-18.

30. Babkair H, Yamazaki M, Uddin MS, Maruyama S, Abe T,
Essa A, Sumita Y, Ahsan MS, Swelam W, Cheng J, Saku
T. Aberrant expression of the tight junction molecules
claudin-1 and zonula occludens-1 mediates cell growth and
invasion in oral squamous cell carcinoma. Hum. Pathol.
2016; 57: 51-60.

19. Gaspar P, Tapon N. Sensing the local environment: actin
architecture and Hippo signalling. Curr. Opin. Cell Biol.
2014; 31: 74-83.

31. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter
L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE.
Immunohistochemical detection and quantitation of
P-glycoprotein in multiple drug-resistant human myeloma
cells: association with level of drug resistance and drug
accumulation. Blood. 1989; 73: 747-752.

20. Dupont S. Role of YAP/TAZ in cell-matrix adhesionmediated signalling and mechanotransduction. Exp. Cell
Res. 2016; 343: 42-53.
21. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta
S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie
E, Hollmig K, Pineda-Roman M, et al. The molecular
classification of multiple myeloma. Blood. 2006; 108:
2020-2028.

32. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent
JM. Development and characterization of a melphalanresistant human multiple myeloma cell line. Cancer Res.
1991; 51: 995-1002.

22. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC,
Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN,
Reich M, Hieronymus H, Wei G, et al. The Connectivity
Map: using gene-expression signatures to connect small
molecules, genes, and disease. Science. 2006; 313: 19291935.

33. Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker
MP, Cress AE, Greenberger LW, De Jong MC, Dalton
WS. Multiple mechanisms confer drug resistance to
mitoxantrone in the human 8226 myeloma cell line. Cancer
Res. 1999; 59: 1021-1028.
34. O’Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel
S, Delmore J, Richardson P, Anderson K, Clynes M,
Mitsiades CS, O’Gorman P. The interaction of bortezomib
with multidrug transporters: implications for therapeutic
applications in advanced multiple myeloma and other
neoplasias. Cancer Chemother. Pharmacol. 2013; 71: 13571368.

23. Li B, Fu J, Chen P, Ge X, Li Y, Kuiatse I, Wang H, Wang
H, Zhang X, Orlowski RZ. The nuclear factor (erythroidderived 2)-like 2 and proteasome maturation protein axis
mediate bortezomib resistance in multiple myeloma. J. Biol.
Chem. 2015; 290: 29854-29868.
24. Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier
JM, Khaw SL, Lessene G, Spencer A, Herold MJ, Roberts
AW, Huang DC. Hierarchy for targeting pro-survival BCL2
family proteins in multiple myeloma: pivotal role of MCL1.
Blood. 2016; 128: 1834-1844.

35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S,
Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, Mesirov JP. Gene set enrichment analysis:
a knowledge-based approach for interpreting genome-wide
expression profiles. Proc. Natl. Acad. Sci. USA. 2005; 102:
15545-15550.

25. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL,
Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN,
Moujalled DM, Bruno A, Csekei M, Paczal A, et al. The
MCL1 inhibitor S63845 is tolerable and effective in diverse
cancer models. Nature. 2016; 538: 477-482.

36. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato
A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti
A, Daidone MG, Dupont S, Basso G, et al. The Hippo
transducer TAZ confers cancer stem cell-related traits on
breast cancer cells. Cell. 2011; 147: 759-772.

26. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou
AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M,
Campbell LL, Polyak K, Brisken C, et al. The epithelialmesenchymal transition generates cells with properties of
stem cells. Cell. 2008; 133: 704-715.

37. Diamantopoulou Z, White G, Fadlullah MZH, Dreger
M, Pickering K, Maltas J, Ashton G, MacLeod R, Baillie
GS, Kouskoff V, Lacaud G, Murray GI, Sansom OJ, et
al. TIAM1 antagonizes TAZ/YAP both in the destruction
complex in the cytoplasm and in the nucleus to inhibit
invasion of intestinal epithelial cells. Cancer Cell. 2017;
31: 621-634.e6.

27. Zeisberg M, Neilson EG. Biomarkers for epithelialmesenchymal transitions. J. Clin. Invest. 2009; 119: 14291437.
28. Kleeff J, Shi X, Bode HP, Hoover K, Shrikhande S, Bryant
PJ, Korc M, Buchler MW, Friess H. Altered expression and
localization of the tight junction protein ZO-1 in primary
and metastatic pancreatic cancer. Pancreas. 2001; 23: 259265.

38. Schmidt EE, Pelz O, Buhlmann S, Kerr G, Horn T, Boutros
M. GenomeRNAi: a database for cell-based and in vivo
RNAi phenotypes, 2013 update. Nucl. Acids Res. 2013; 41:
D1021-6.

29. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown
E, Herlyn M. Up-regulated expression of zonula occludens
www.impactjournals.com/oncoscience

39. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad
R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM,
14

Oncoscience

Sacco A, Ngo HT, et al. Hypoxia promotes dissemination
of multiple myeloma through acquisition of epithelial to
mesenchymal transition-like features. Blood. 2012; 119:
5782-5794.

51. Remue E, Meerschaert K, Oka T, Boucherie C,
Vandekerckhove J, Sudol M, Gettemans J. TAZ interacts
with zonula occludens-1 and -2 proteins in a PDZ-1
dependent manner. FEBS Lett. 2010; 584: 4175-4180.

40. Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB,
Ely SA, Osman K, Zhang Y, Kalakonda N, Nimer SD.
Insights into extramedullary tumour cell growth revealed by
expression profiling of human plasmacytomas and multiple
myeloma. Br. J. Haematol. 2003; 122: 728-744.

52. Gottardi CJ, Arpin M, Fanning AS, Louvard D. The
junction-associated protein, zonula occludens-1, localizes to
the nucleus before the maturation and during the remodeling
of cell-cell contacts. Proc. Natl. Acad. Sci. USA. 1996; 93:
10779-10784.

41. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B,
Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A,
Van Rhee F, Crowley J, Barlogie B. Extramedullary disease
portends poor prognosis in multiple myeloma and is overrepresented in high-risk disease even in the era of novel
agents. Haematologica. 2012; 97: 1761-1767.

53. Polette M, Mestdagt M, Bindels S, Nawrocki-Raby B,
Hunziker W, Foidart JM, Birembaut P, Gilles C. β-Catenin
and ZO-1: shuttle molecules involved in tumor invasionassociated epithelial-mesenchymal transition processes.
Cells Tissues Organs. 2007; 185: 61-65.
54. Van Itallie CM, Tietgens AJ, Krystofiak E, Kachar B,
Anderson JM. A complex of ZO-1 and the BAR-domain
protein TOCA-1 regulates actin assembly at the tight
junction. Mol. Biol. Cell. 2015; 26: 2769-2787.

42. Goswami CP, Nakshatri H. PROGgeneV2: enhancements
on the existing database. BMC Cancer. 2014; 14: 970-240714-970.
43. Bianchi A, Gervasi ME, Bakin A. Role of β5-integrin in
epithelial-mesenchymal transition in response to TGF-β.
Cell Cycle. 2010; 9: 1647-1659.

55. Tam LC, Reina-Torres E, Sherwood JM, Cassidy PS,
Crosbie DE, Lutjen-Drecoll E, Flugel-Koch C, Perkumas
K, Humphries MM, Kiang AS, O’Callaghan J, Callanan
JJ, Read AT, et al. Enhancement of outflow facility in
the murine eye by targeting selected tight-junctions of
Schlemm’s canal endothelia. Sci. Rep. 2017; 7: 40717.

44. Fan J, Ponferrada VG, Sato T, Vemaraju S, Fruttiger M,
Gerhardt H, Ferrara N, Lang RA. Crim1 maintains retinal
vascular stability during development by regulating
endothelial cell Vegfa autocrine signaling. Development.
2014; 141: 448-459.

56. Cuyas E, Martin-Castillo B, Corominas-Faja B, Massaguer
A, Bosch-Barrera J, Menendez JA. Anti-protozoal and antibacterial antibiotics that inhibit protein synthesis kill cancer
subtypes enriched for stem cell-like properties. Cell Cycle.
2015; 14: 3527-3532.

45. Zhang Y, Fan J, Ho JW, Hu T, Kneeland SC, Fan X, Xi Q,
Sellarole MA, de Vries WN, Lu W, Lachke SA, Lang RA,
John SW, et al. Crim1 regulates integrin signaling in murine
lens development. Development. 2016; 143: 356-366.

57. Visnyei K, Onodera H, Damoiseaux R, Saigusa K,
Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan EH,
Masterman-Smith M, Mottahedeh J, Bradley KA, Huang
J, et al. A molecular screening approach to identify and
characterize inhibitors of glioblastoma stem cells. Mol.
Cancer. Ther. 2011; 10: 1818-1828.

46. Bock J, Mochmann LH, Schlee C, Farhadi-Sartangi
N, Gollner S, Muller-Tidow C, Baldus CD. ERG
transcriptional networks in primary acute leukemia cells
implicate a role for ERG in deregulated kinase signaling.
PLoS One. 2013; 8: e52872.

58. Alvandi F, Kwitkowski VE, Ko CW, Rothmann MD,
Ricci S, Saber H, Ghosh D, Brown J, Pfeiler E, Chikhale
E, Grillo J, Bullock J, Kane R, et al. U.S. Food and
Drug Administration approval summary: omacetaxine
mepesuccinate as treatment for chronic myeloid leukemia.
Oncologist. 2014; 19: 94-99.

47. Prenkert M, Uggla B, Tidefelt U, Strid H. CRIM1 is
expressed at higher levels in drug-resistant than in drugsensitive myeloid leukemia HL60 cells. Anticancer Res.
2010; 30: 4157-4161.
48. Barretina J, Caponigro G, Stransky N, Venkatesan K,
Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV,
Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer
Cell Line Encyclopedia enables predictive modelling of
anticancer drug sensitivity. Nature. 2012; 483: 603-607.

59. Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E,
Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka
R, Andreeff M, Taniwaki M, Maekawa T. Anti-myeloma
effect of homoharringtonine with concomitant targeting
of the myeloma-promoting molecules, Mcl-1, XIAP, and
β-catenin. Int. J. Hematol. 2008; 87: 507-515.

49. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S,
Hose D, Goldschmidt H, Jauch A, Reme T, Jourdan M,
Amiot M, Pellat-Deceunynck C. A high-risk signature
for patients with multiple myeloma established from the
molecular classification of human myeloma cell lines.
Haematologica. 2011; 96: 574-582.

60. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li
T, Chan SW, Lim CJ, Hong W, Zhao S, Xiong Y, Lei QY, et
al. The hippo tumor pathway promotes TAZ degradation by
phosphorylating a phosphodegron and recruiting the SCFβTrCP E3 ligase. J. Biol. Chem. 2010; 285: 37159-37169.

50. Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim
J. Actin remodeling confers BRAF inhibitor resistance to
melanoma cells through YAP/TAZ activation. EMBO J.
2016; 35: 462-478.

www.impactjournals.com/oncoscience

61. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt
J, Wolf J, Chen W, Selbach M. Global quantification of
mammalian gene expression control. Nature. 2011; 473:
15

Oncoscience

337-342.
62. Harder B, Tian W, La Clair JJ, Tan AC, Ooi A, Chapman E,
Zhang DD. Brusatol overcomes chemoresistance through
inhibition of protein translation. Mol. Carcinog. 2017; 56:
1493-1500.
63. Zihni C, Mills C, Matter K, Balda MS. Tight junctions:
from simple barriers to multifunctional molecular gates.
Nat. Rev. Mol. Cell Biol. 2016; 17: 564-580.
64. Lv XB, Liu CY, Wang Z, Sun YP, Xiong Y, Lei QY, Guan
KL. PARD3 induces TAZ activation and cell growth by
promoting LATS1 and PP1 interaction. EMBO Rep. 2015;
16: 975-985.
65. Riou P, Villalonga P, Ridley AJ. Rnd proteins:
multifunctional regulators of the cytoskeleton and cell cycle
progression. Bioessays. 2010; 32: 986-992.
66. Paysan L, Piquet L, Saltel F, Moreau V. Rnd3 in cancer: a
review of the evidence for tumor promoter or suppressor.
Mol. Cancer Res. 2016; 14: 1033-1044.
67. Rubenstein NM, Chan JF, Kim JY, Hansen SH, Firestone
GL. Rnd3/RhoE induces tight junction formation in
mammary epithelial tumor cells. Exp. Cell Res. 2005; 305:
74-82.
68. Guasch RM, Scambler P, Jones GE, Ridley AJ. RhoE
regulates actin cytoskeleton organization and cell migration.
Mol. Cell. Biol. 1998; 18: 4761-4771.
69. Klein RM, Aplin AE. Rnd3 regulation of the actin
cytoskeleton promotes melanoma migration and invasive
outgrowth in three dimensions. Cancer Res. 2009; 69: 22242233.
70. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell
detachment activates the Hippo pathway via cytoskeleton
reorganization to induce anoikis. Genes Dev. 2012; 26: 5468.
71. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F,
Elvassore N, Dupont S, Piccolo S. A mechanical checkpoint
controls multicellular growth through YAP/TAZ regulation
by actin-processing factors. Cell. 2013; 154: 1047-1059.

www.impactjournals.com/oncoscience

16

Oncoscience

